Company Overview of Prexton Therapeutics SA
Prexton Therapeutics SA develops Parkinson’s drugs that target the metabotropic glutamate receptors mGluR3 and mGluR4. The company was founded in 2012 and is based in Geneva, Switzerland.
Chemin des Aulx 14
Founded in 2012
Key Executives for Prexton Therapeutics SA
Prexton Therapeutics SA Key Developments
Similar Private Companies By Industry
|FunZyme BioTechnologies S.A.||Europe|
|TopoTarget Switzerland S.A.||Europe|
Recent Private Companies Transactions
February 24, 2015
To contact Prexton Therapeutics SA, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.